SG11201903463PA - Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same - Google Patents

Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same

Info

Publication number
SG11201903463PA
SG11201903463PA SG11201903463PA SG11201903463PA SG11201903463PA SG 11201903463P A SG11201903463P A SG 11201903463PA SG 11201903463P A SG11201903463P A SG 11201903463PA SG 11201903463P A SG11201903463P A SG 11201903463PA SG 11201903463P A SG11201903463P A SG 11201903463PA
Authority
SG
Singapore
Prior art keywords
same
quinolyl
pharmaceutically acceptable
carboxylic acid
acceptable salt
Prior art date
Application number
SG11201903463PA
Inventor
Zhiqiang Zhang
Xijuan Wang
Xuehui Zhang
Junxia Qiu
Jiehe Yang
Xiaokai Zhang
Peng Yao
Original Assignee
Beijing Konruns Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Konruns Pharmaceutical Co Ltd filed Critical Beijing Konruns Pharmaceutical Co Ltd
Publication of SG11201903463PA publication Critical patent/SG11201903463PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present application provides a quinolyl-substituted carboxylic acid compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, as well as a method for preparing the compound, a use of the compound, and a formulation containing the quinolyl-substituted carboxylic acid compound or the pharmaceutically acceptable salt thereof. This type of compounds are inhibitors for AXL and/or VEGFR2 protein kinase, and can be used to treat diseases caused by abnormality of the two protein kinases, such as, tumor, etc.;
SG11201903463PA 2016-10-18 2017-09-29 Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same SG11201903463PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610909448 2016-10-18
PCT/CN2017/104518 WO2018072614A1 (en) 2016-10-18 2017-09-29 Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof

Publications (1)

Publication Number Publication Date
SG11201903463PA true SG11201903463PA (en) 2019-05-30

Family

ID=62018194

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903463PA SG11201903463PA (en) 2016-10-18 2017-09-29 Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same

Country Status (10)

Country Link
US (1) US10723701B2 (en)
EP (1) EP3530654B1 (en)
JP (1) JP6875537B2 (en)
KR (1) KR102262280B1 (en)
CN (1) CN109496212B (en)
AU (1) AU2017346104B2 (en)
CA (1) CA3040788C (en)
SG (1) SG11201903463PA (en)
TW (1) TWI742181B (en)
WO (1) WO2018072614A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021014504A2 (en) * 2019-01-25 2021-09-28 Exelixis, Inc. COMPOUNDS FOR THE TREATMENT OF KINASE DEPENDENT DISORDERS
AU2020255702B2 (en) * 2019-04-03 2023-04-13 Primegene (Beijing) Co., Ltd. Quinolyl-containing compound and pharmaceutical composition, and use thereof
CN111825609A (en) * 2019-04-22 2020-10-27 北京康辰药业股份有限公司 Compound crystal form, preparation method, pharmaceutical composition and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0101675D0 (en) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
RU2011142597A (en) * 2009-03-21 2013-04-27 Саншайн Лейк Фарма Ко., Лтд. DERIVATIVES OF COMPOUND ETHERS OF AMINO ACIDS, THEIR SALTS AND METHODS OF APPLICATION
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CN102093421B (en) * 2011-01-28 2014-07-02 北京康辰药业有限公司 Phosphorus substituent group-containing quinoline compound and preparation method of quinoline compound as well as pharmaceutical composition containing quinoline compound and application of pharmaceutical composition
CN102408411B (en) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 Hydroximic acid compound containing quinolyl and preparation method thereof, and drug composition containing the compound and use thereof
EA201490944A1 (en) * 2011-11-08 2014-10-30 Экселиксис, Инк. DOUBLE MET AND VEGF INHIBITOR FOR CANCER TREATMENT

Also Published As

Publication number Publication date
KR20190066626A (en) 2019-06-13
EP3530654A4 (en) 2020-04-22
AU2017346104A1 (en) 2019-05-16
JP6875537B2 (en) 2021-05-26
JP2019531354A (en) 2019-10-31
EP3530654A1 (en) 2019-08-28
CN109496212B (en) 2020-08-14
AU2017346104B2 (en) 2020-06-11
US10723701B2 (en) 2020-07-28
EP3530654B1 (en) 2022-12-14
US20190256470A1 (en) 2019-08-22
CA3040788C (en) 2022-01-11
TWI742181B (en) 2021-10-11
CN109496212A (en) 2019-03-19
WO2018072614A1 (en) 2018-04-26
KR102262280B1 (en) 2021-06-09
TW201815765A (en) 2018-05-01
CA3040788A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA201691151A1 (en) CONNECTIONS FOR THE TREATMENT OF PATIENTS WITH ROS1-MUTANT CANCER CELLS
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
MX2013012981A (en) Substituted indazole derivatives active as kinase inhibitors.
MD4800B1 (en) Aminopyrimidinyl compounds as JAK inhibitors
EA201791018A1 (en) DERIVATIVES OF 6-AMINO-7-BICYCLO-7-DEAZAPURIN AS PROTECTINININASE INHIBITORS
MY189761A (en) Quinazoline derivatives used to treat hiv
MX2015009950A (en) Imidazopyridine compounds and uses thereof.
BR112015028501B8 (en) BIPYRAZOLE DERIVATIVE COMPOUNDS, THEIR SALTS, COMPOSITION COMPRISING THE COMPOUND OR THE SALT, METHOD FOR IN VITRO INHIBITION OF A JAK1 ACTIVITY, AND PROCESS FOR PREPARING PHOSPHORIC ACID SALT
EA201690752A1 (en) INHIBITORS G12C KRAS
EA201790246A1 (en) HETEROCYCLIC CARBONIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATZYCLIC
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
MX336051B (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors.
EA201592238A1 (en) PI3K PROTEINKINASE INHIBITORS, IN PARTICULAR PI3K DELTA AND / OR GAMMA INHIBITORS
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
MX2016008665A (en) 1,2-naphthoquinone derivative and method for preparing same.
TN2015000574A1 (en) Compounds and compositions as inhibitors of mek
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
SA519401322B1 (en) Heteroaryl carboxamide compounds as inhibitors of receptor-interacting serine/threonine protein kinase 2
GB201302704D0 (en) Therapeutic compounds
MY194873A (en) Fused Bicyclic Heteroaryl Derivatives Having Activity as Phd Inhibitors
EA201991355A1 (en) IMIDAZO [1,5-A] PYRASINE DERIVATIVES AS PI3K DELTA INHIBITORS
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA201790830A1 (en) ALDOSTERONSYNTASE INHIBITORS